After meeting with FDA officials about its E5 anti-endotoxinmonoclonal antibody, Xoma Corp. said Thursday that it willsubmit additional data and analyses from the two completedrandomized, multicenter, placebo-controlled E5 studies.

The company announced June 4 that the FDA might requestadditional clinical testing of E5 to support Xoma's productlicense application, a move that sent Xoma's stock(NASDAQ:XOMA) down. The Berkeley, Calif., company hopesthat the additional information it plans to submit will provesufficient. A company spokeswoman declined to speculateThursday on when the FDA might decide the issue.

(c) 1997 American Health Consultants. All rights reserved.